Radioactive iodine uptake test
The radioactive iodine uptake test is a type of scan used in the diagnosis of thyroid problems, particularly hyperthyroidism. It is entirely different from radioactive iodine therapy (RAI therapy), which uses much higher doses to destroy cancerous cells. The RAIU test is also used as a follow up to RAI therapy to verify that no thyroid cells survived, which could still be cancerous. The patient swallows a radioisotope of iodine in the form of capsule or fluid, and the absorption (uptake) of this radiotracer by the thyroid is studied after 4–6 hours and after 24 hours  with the aid of a scintillation counter. The dose is typically 0.15–0.37 MBq (4–10 μCi) of I iodide, or 3.7–7.4 MBq (100–200 μCi) of I iodide. The RAIU test is a reliable measurement when using a dedicated probe with a reproducibility of 1 percent and a 95%-least-significant-change of 3 percent. The normal uptake is between 15 and 25 percent, but this may be forced down if, in the meantime, the patient has eaten foods high in iodine, such as dairy products and seafood. Low uptake suggests thyroiditis, high uptake suggests Graves' disease, and unevenness in uptake suggests the  presence of a nodule. I has a shorter half-life than I (a half day vs. 8.1 days), so use of I exposes the body to less radiation, at the expense of less time to evaluate delayed scan images. Furthermore, I emits gamma radiation, while I emits gamma and beta radiation. Contraindications. The test is inappropriate for patients who are pregnant or breastfeeding. Additional images. LMP BNUKSEA 4000+60000